Combined Analyses of Participants with Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated with Efgartigimod Across Clinical Studies (P1-11.029)
To describe the efficacy of efgartigimod, a human immunoglobulin G1 (IgG1) antibody Fc-fragment that blocks the neonatal Fc receptor (FcRn), in anti-acetylcholine receptor antibody negative (AChR-Ab−) participants with generalized myasthenia gravis (gMG) receiving either efgartigimod IV or subcutaneous (SC) efgartigimod PH20 (coformulated with recombinant human hyaluronidase PH20).
Authors
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Edward Brauer
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Tuan H. Vu (ORCID: https://orcid.org/0000-0001-6839-9765)
- Andreas Meisel (ORCID: https://orcid.org/0000-0001-7233-5342)
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
Institutions
- University Health Network (CA)
- University of South Florida (US)
- Health Net (US)
- National Hospital Organization Hanamaki Hospital (JP)
- Argenx (Belgium) (BE)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210567
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00